PMC:7461420 / 42553-43027 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T219","span":{"begin":89,"end":93},"obj":"Disease"},{"id":"T220","span":{"begin":402,"end":412},"obj":"Disease"},{"id":"T221","span":{"begin":413,"end":423},"obj":"Disease"}],"attributes":[{"id":"A219","pred":"mondo_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A220","pred":"mondo_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A221","pred":"mondo_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/MONDO_0003781"}],"text":"Another peptidic drug with a Michael acceptor was N3 (40), which was reported to inhibit SARS‐CoV‐1 3CLpro (K i, 9.0 µM) by Yang et al. It was observed to be a broad‐spectrum antiviral compound, also inhibiting other CoVs, such as MERS‐CoV Mpro (IC50, 0.28µM), 135 HCoV‐229E, HCoV‐NL63, and HCoV‐HKU1 Mpro. 135 , 136 , 137 , 138 It has also exhibited high antiviral activity in an animal model of infectious bronchitis virus. 137 The CC50 of 40 is greater than 133 μM."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T519","span":{"begin":8,"end":16},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T520","span":{"begin":27,"end":28},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T521","span":{"begin":158,"end":159},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T522","span":{"begin":337,"end":340},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T523","span":{"begin":371,"end":379},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T524","span":{"begin":386,"end":392},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"},{"id":"T525","span":{"begin":424,"end":429},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Another peptidic drug with a Michael acceptor was N3 (40), which was reported to inhibit SARS‐CoV‐1 3CLpro (K i, 9.0 µM) by Yang et al. It was observed to be a broad‐spectrum antiviral compound, also inhibiting other CoVs, such as MERS‐CoV Mpro (IC50, 0.28µM), 135 HCoV‐229E, HCoV‐NL63, and HCoV‐HKU1 Mpro. 135 , 136 , 137 , 138 It has also exhibited high antiviral activity in an animal model of infectious bronchitis virus. 137 The CC50 of 40 is greater than 133 μM."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T444","span":{"begin":17,"end":21},"obj":"Chemical"},{"id":"T445","span":{"begin":37,"end":45},"obj":"Chemical"},{"id":"T446","span":{"begin":175,"end":184},"obj":"Chemical"},{"id":"T447","span":{"begin":361,"end":370},"obj":"Chemical"}],"attributes":[{"id":"A444","pred":"chebi_id","subj":"T444","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A445","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_15339"},{"id":"A446","pred":"chebi_id","subj":"T446","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A447","pred":"chebi_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Another peptidic drug with a Michael acceptor was N3 (40), which was reported to inhibit SARS‐CoV‐1 3CLpro (K i, 9.0 µM) by Yang et al. It was observed to be a broad‐spectrum antiviral compound, also inhibiting other CoVs, such as MERS‐CoV Mpro (IC50, 0.28µM), 135 HCoV‐229E, HCoV‐NL63, and HCoV‐HKU1 Mpro. 135 , 136 , 137 , 138 It has also exhibited high antiviral activity in an animal model of infectious bronchitis virus. 137 The CC50 of 40 is greater than 133 μM."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T17","span":{"begin":413,"end":423},"obj":"Phenotype"}],"attributes":[{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0012387"}],"text":"Another peptidic drug with a Michael acceptor was N3 (40), which was reported to inhibit SARS‐CoV‐1 3CLpro (K i, 9.0 µM) by Yang et al. It was observed to be a broad‐spectrum antiviral compound, also inhibiting other CoVs, such as MERS‐CoV Mpro (IC50, 0.28µM), 135 HCoV‐229E, HCoV‐NL63, and HCoV‐HKU1 Mpro. 135 , 136 , 137 , 138 It has also exhibited high antiviral activity in an animal model of infectious bronchitis virus. 137 The CC50 of 40 is greater than 133 μM."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1277","span":{"begin":302,"end":306},"obj":"Gene"},{"id":"1278","span":{"begin":240,"end":244},"obj":"Gene"},{"id":"1279","span":{"begin":89,"end":97},"obj":"Species"},{"id":"1280","span":{"begin":217,"end":221},"obj":"Species"},{"id":"1281","span":{"begin":231,"end":239},"obj":"Species"},{"id":"1282","span":{"begin":266,"end":275},"obj":"Species"},{"id":"1283","span":{"begin":277,"end":286},"obj":"Species"},{"id":"1284","span":{"begin":292,"end":301},"obj":"Species"},{"id":"1285","span":{"begin":402,"end":429},"obj":"Species"}],"attributes":[{"id":"A1277","pred":"tao:has_database_id","subj":"1277","obj":"Gene:8673700"},{"id":"A1278","pred":"tao:has_database_id","subj":"1278","obj":"Gene:8673700"},{"id":"A1279","pred":"tao:has_database_id","subj":"1279","obj":"Tax:694009"},{"id":"A1280","pred":"tao:has_database_id","subj":"1280","obj":"Tax:11118"},{"id":"A1281","pred":"tao:has_database_id","subj":"1281","obj":"Tax:1335626"},{"id":"A1282","pred":"tao:has_database_id","subj":"1282","obj":"Tax:11137"},{"id":"A1283","pred":"tao:has_database_id","subj":"1283","obj":"Tax:277944"},{"id":"A1284","pred":"tao:has_database_id","subj":"1284","obj":"Tax:290028"},{"id":"A1285","pred":"tao:has_database_id","subj":"1285","obj":"Tax:11120"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Another peptidic drug with a Michael acceptor was N3 (40), which was reported to inhibit SARS‐CoV‐1 3CLpro (K i, 9.0 µM) by Yang et al. It was observed to be a broad‐spectrum antiviral compound, also inhibiting other CoVs, such as MERS‐CoV Mpro (IC50, 0.28µM), 135 HCoV‐229E, HCoV‐NL63, and HCoV‐HKU1 Mpro. 135 , 136 , 137 , 138 It has also exhibited high antiviral activity in an animal model of infectious bronchitis virus. 137 The CC50 of 40 is greater than 133 μM."}

{"project":"LitCovid-sentences","denotations":[{"id":"T389","span":{"begin":0,"end":135},"obj":"Sentence"},{"id":"T390","span":{"begin":136,"end":307},"obj":"Sentence"},{"id":"T391","span":{"begin":308,"end":430},"obj":"Sentence"},{"id":"T392","span":{"begin":431,"end":474},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Another peptidic drug with a Michael acceptor was N3 (40), which was reported to inhibit SARS‐CoV‐1 3CLpro (K i, 9.0 µM) by Yang et al. It was observed to be a broad‐spectrum antiviral compound, also inhibiting other CoVs, such as MERS‐CoV Mpro (IC50, 0.28µM), 135 HCoV‐229E, HCoV‐NL63, and HCoV‐HKU1 Mpro. 135 , 136 , 137 , 138 It has also exhibited high antiviral activity in an animal model of infectious bronchitis virus. 137 The CC50 of 40 is greater than 133 μM."}